Filing Details
- Accession Number:
- 0001689375-23-000048
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-12 16:34:51
- Reporting Period:
- 2023-07-10
- Accepted Time:
- 2023-07-12 16:34:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1689375 | Entrada Therapeutics Inc. | TRDA | Pharmaceutical Preparations (2834) | 813983399 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1725663 | James Kory Wentworth | C/O Entrada Therapeutics, Inc. One Design Center Place, Suite 17-500 Boston MA 02210 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-07-10 | 6,116 | $2.10 | 42,863 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-07-10 | 6,116 | $17.98 | 36,747 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-07-11 | 3,884 | $2.10 | 40,631 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-07-11 | 3,884 | $18.00 | 36,747 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-07-10 | 6,116 | $0.00 | 6,116 | $2.10 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-07-11 | 3,884 | $0.00 | 3,884 | $2.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 68,541 | 2030-11-10 | No | 4 | M | Direct | |
| 64,657 | 2030-11-10 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
